Literature DB >> 27893021

Mitigating Financial Toxicity Among US Patients With Cancer.

Jonas A de Souza1, Rena M Conti2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 27893021     DOI： 10.1001/jamaoncol.2016.4850

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

1.  Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.

Authors:  Scott K Sherman; Joel J Lange; Fadi S Dahdaleh; Rahul Rajeev; T Clark Gamblin; Blase N Polite; Kiran K Turaga
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

2.  First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.

Authors:  XiaoMin Wan; YuCong Zhang; ChongQing Tan; XiaoHui Zeng; LiuBao Peng
Journal:  JAMA Oncol       Date:  2019-04-01       Impact factor: 31.777

3.  Assessing disparities in colorectal cancer mortality by socioeconomic status using new tools: health disparities calculator and socioeconomic quintiles.

Authors:  Nancy Breen; Denise Riedel Lewis; James Todd Gibson; Mandi Yu; Sam Harper
Journal:  Cancer Causes Control       Date:  2017-01-12       Impact factor: 2.506

4.  Global comparison of cancer outcomes: standardization and correlation with healthcare expenditures.

Authors:  Horace C W Choi; Ka-On Lam; Herbert H M Pang; Steven K C Tsang; Roger K C Ngan; Anne W M Lee
Journal:  BMC Public Health       Date:  2019-08-07       Impact factor: 3.295

5.  Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.

Authors:  Francesco Trotta; Flavia Mayer; Francesco Barone-Adesi; Immacolata Esposito; Ranadhir Punreddy; Roberto Da Cas; Giuseppe Traversa; Francesco Perrone; Nello Martini; Bishal Gyawali; Antonio Addis
Journal:  BMJ Open       Date:  2019-12-10       Impact factor: 2.692

6.  Health services utilization, out-of-pocket expenditure, and underinsurance among insured non-elderly cancer survivors in the United States, 2011-2015.

Authors:  Mohammad A Karim; Amit G Singal; Robert L Ohsfeldt; Michael A Morrisey; Hye-Chung Kum
Journal:  Cancer Med       Date:  2021-07-30       Impact factor: 4.452
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.